chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It started as severe pain in my right arm around 3:00 which continued to spread through my hand, shoulder, and chest on just my right side. I noticed that evening I had developed whelps on my arm from my shoulder to my elbow.  Those became swollen and painful to touch. At the same time, I began having severe stomach cramps; my throat/mouth was also dry and itchy. I took Benadryl and Tylenol which reduced the pain. At this time, the whelps and stomach pain are still present, but lessened.  I will be going to my primary care doctor for a check up as soon as they can get me in.
I21.4 ACUTE NON ST ELEVATION MI 4/15/2023 ACUTE NON ST ELEVATION MI
Minor rash at left hand (injection arm) and slight swelling on left side of lips. Symptoms last for about 2 hours. No treatment. Just monitoring.
Patient is currently 2 weeks post booster dose (0.25mL) of Moderna.  After approximately 1 week, patient noticed pain in his left hip.  The pain then progressed down through his knee and into his foot.  Patient now states that the issue has moved over into his right leg and he needs ibuprofen to alleviate the pain and also uses a can to help him mobilize.  Patient is able to function largely because of the relief ibuprofen provides.  Patient has not had to go to hospital or Dr's office because of this issue.  Patient has reported this information to his physician and he is being monitored for worsening of symptoms.
blood pressure was high; at 188/122; one finger on the left side was swollen and was hard to make a fist, it hurts and it feels funny; one finger on the left side was swollen and was hard to make a fist, it hurts and it feels funny; She took the shot Friday (30Jul2021) and they had taken it in the left shoulder. It was swollen that Friday and Saturday, Sunday, Monday and Tuesday and until today and she was at work.; her left hand, the fingers were swollen; This is a spontaneous report from a contactable consumer (patient). A 57-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in arm left (left shoulder) on 30Jul2021 (about 12:15 or 12:30) (Lot Number: FA7485) as DOSE 2, SINGLE for covid-19 immunization. Medical history and family history included high blood pressure. Concomitant medication included losartan taken for high blood pressure from May2021 and from Jun2021. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on 09Jul2021 (lot number EW0198) for covid-19 immunization. The patient was calling regarding the Pfizer Covid vaccine. She took the shot Friday (30Jul2021) and they had taken it in the left shoulder. It was swollen that Friday and Saturday, Sunday, Monday and Tuesday and until today and she was at work. In her left hand, the fingers were swollen. She could not lay on her left arm. It was the fingers on the left side and it was on Monday and Tuesday. Today (04Aug2021), one finger on the left side was swollen and was hard to make a fist, it hurts and it feels funny. It kind of throbs but was kind of the same. The patient did not receive treatment for these events, she just took her blood pressure medicine. The events did not require visit to emergency room but she was going to go today (04Aug2021), this morning when she got up to take her blood pressure pill, her blood pressure was high. It was basically 188/122. Her hand was still swollen. The patient was advised to contact her primary care provider for any medical advice. Outcome of the event "blood pressure was high; at 188/122" was unknown, while not recovered for other events.  Follow-up attempts are completed. No further information is expected.
I had a small reaction to the shot some redness and swelling and a slight fever and chill. However, the there are clusters of small red bumps at the site of where the shot was given. Please advise.
Case number PHEH2014US014074 is an initial spontaneous report from a health care professional received on 07 Jul 2014. This report refers to an 11-year-old male patient. Historical conditions were not reported. No concomitant medication was reported. He was vaccinated with MENVEO (batch number: A12132) intramuscularly at a dose of 0.5 ml on 02 Jul 2014, that had a temperature excursion to 9 degrees Celsius for 1.5 hours on 01 Jul 2014. No adverse event was reported following the medication error (incorrect storage of drug).
Thrombocytopenia, cause petechiae all over the body, ecchymosis on tibia 5 days post vax. Referred to hosp.
red spot a little itchy; quarter size red spot below injection site; injection arm a little sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (red spot a little itchy), VACCINATION SITE PAIN (injection arm a little sore) and VACCINATION SITE ERYTHEMA (quarter size red spot below injection site) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, the patient experienced VACCINATION SITE PAIN (injection arm a little sore). On 26-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (red spot a little itchy) and VACCINATION SITE ERYTHEMA (quarter size red spot below injection site). On 18-Mar-2021, VACCINATION SITE PAIN (injection arm a little sore) had resolved. At the time of the report, VACCINATION SITE PRURITUS (red spot a little itchy) and VACCINATION SITE ERYTHEMA (quarter size red spot below injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.   Treatment information was not provided.    Most recent FOLLOW-UP information incorporated above includes: On 13-May-2021: Reporter's address was updated, Patient's demographic details (age) and route of administration of vaccine was added.
Feb-26-2004 sore throat, hoarseness, fever, chills, coughing, up a lots of flem, running nose, soreness in eyes and nose. Weakness,appetite change, nauseated. Last till March 1st. Left me weak tired, no appetite. Went into health center was not treated March 9 2004.
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and unknown gender. The patient pertinent medical history was not reported. On 03-NOV-2014, the patient was vaccinated with PROQUAD (Merck) (dose strength and route was not reported) (lot # K007797 and expiry date: 29-NOV-2015) which was improperly stored. Primary reporter was reporting excursion of 6 F since 01-JUN-2013 (confirmed date) affecting PROQUAD (Merck), nurse also reported that products were not stored in an overall average support range of -58 degree F and 5 degree F. No adverse effects reported. No product quality complaint (PQC) was reported for PROQUAD (Merck). This is one of the several reports from the same reporter. Additional information has been requested.
After receiving the vaccine in right arm on 1/13 I had injection site pain and an severe upset stomach until 1/19. I was fatigued from 1/13 until 1/24. On Friday Jan 15 the pain in my injection site improved, but the pain moved to my right collar bone and right side of neck muscles. On Jan 16 the pain returned to the injection site and increasingly got worse in my collar bone and neck. The pain continued to worsen and become intolerable on 1/20. On 1/20 I was having pain in my injection site, collar bone, neck muscles, and my throat was sore and hurt to swallow. I went to the ER . After going to the ER and waiting for medications to be ready at the pharmacy the pain moved into my ear and I had a severe ear ache for two days. My symptoms improved after 2 days with ibuprofen 3x/day, muscle relaxers 3x/ day, Benadryl and lidocaine patches. The pain was localized to the right side of body and did limit the ability to complete ADLs
her injection site is still bruised; randomly started bleeding a bit/ bleeding at immunization site; This is a spontaneous report from a contactable consumer (Patient) via Regulatory Authority.   A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: ER8730), via an unspecified route of administration in left arm on 24Mar2021 at 13:00 as dose 1, single for COVID-19 immunisation at clinic. The patient's medical history and concomitant medications were reported as none. The patient's past drug included vitamins. Patient's family medical history relevant to event was reported as none. Patient did not receive any other vaccine within four weeks prior to the first administration date of the suspect vaccine. On 26Mar2021, a couple of days after getting the immunization, the patient's injection site was still bruised. While it was getting better, the bruise persisted and on an unspecified date, in 2021, it randomly started bleeding a bit. Patient's arm did bleed when she got the shot, but then stopped right after. The patient received treatment for the events. The clinical outcome of the events was resolving.  No follow-up attempts are possible; Information about lot/batch number cannot be obtained.
Nose bleeding; Blood pressure high 163/95; Swollen lymph node; This spontaneous case was reported by a consumer and describes the occurrence of EPISTAXIS (Nose bleeding), HYPERTENSION (Blood pressure high 163/95) and LYMPHADENOPATHY (Swollen lymph node) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 939903, 023M20A and 032LZ0A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced LYMPHADENOPATHY (Swollen lymph node). On 24-Nov-2021, the patient experienced EPISTAXIS (Nose bleeding) and HYPERTENSION (Blood pressure high 163/95). The patient was treated with PARACETAMOL (PANADOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, EPISTAXIS (Nose bleeding), HYPERTENSION (Blood pressure high 163/95) and LYMPHADENOPATHY (Swollen lymph node) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Nov-2021, Blood pressure measurement: 163/95 (High) 163/95.         It was reported that the patient still had the symptoms ongoing. No concomitant medications were reported
Headache, muscle and joint pain, loss of appetite nausea, fatigue, dizziness.
Loss of appetite, inability to control bladder, diarrhea, sluggish, weaknesses, and sleeping a lot.
Father states he found patient face down, "blue" and having a seizure. Called EMS. Seen at ER, temp 102.9, R P176, R28, CXR negative. Dx fever. Treated with Motrin and released at 10:38 AM.
Chills; Sweating; Tired; Sore arm/achy arms; Zero energy; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A patient (no qualifiers provided) received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CHILLS (non-serious), outcome "unknown", described as "Chills"; HYPERHIDROSIS (non-serious), outcome "unknown", described as "Sweating"; FATIGUE (non-serious), outcome "unknown", described as "Tired"; PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "Sore arm/achy arms"; ASTHENIA (non-serious), outcome "unknown", described as "Zero energy".  Follow-up attempts have been completed and no further information is expected.
sharp pain (bearable) but it is distinct in jaw. In the scale of 1-10 the pain is around 2-3 I can say. It is kind of pain come and go with intervals..of few secs.
One day after injection, patient noted lymph node swelling in the left axilla and neck. No treatment needed. By follow-up appt 10/21/15 symptoms had essentially resolved.
a rash in her upper body/a rash in her torso after the 2nd dose/ rash is still there, on  face, back, thighs, all in different places, it's getting better, but it hasn't disappeared; This spontaneous case was reported by a consumer and describes the occurrence of RASH (a rash in her upper body/a rash in her torso after the 2nd dose/ rash is still there, on  face, back, thighs, all in different places, it's getting better, but it hasn't disappeared) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022B21A and 024C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RASH (a rash in her upper body/a rash in her torso after the 2nd dose/ rash is still there, on  face, back, thighs, all in different places, it's getting better, but it hasn't disappeared). The patient was treated with PREDNISONE for Rash, at a dose of UNK dosage form and HYDROXYZINE for Rash, at a dose of UNK dosage form. At the time of the report, RASH (a rash in her upper body/a rash in her torso after the 2nd dose/ rash is still there, on  face, back, thighs, all in different places, it's getting better, but it hasn't disappeared) outcome was unknown.            No concomitant medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 28-Jun-2021: Additional1
CLIENT PRESENTED TO CLINIC  FOR FIRST DOSE PFIZER; TOLD VACXCINATOR AND DATA STAFF SHE WAS 11 YEARS OLD; PARENTS HAD LANGUAGE BARRIER AND CHILD EXP;LAINGTO PARENTS VACCINE PROCEDURE; PROVIDED PFIZER PEDIATRIC VACCINE; COUNSELED VACCINATOR AND DATA OF CORRECT AGE FOR PEDIATRIC, USE OF ELECTRONIC TRANSLATION WITH LANGUAGE LINE AND STANDING ORDERS.
This spontaneous report was received from a healthcare worker and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, concomitant medication and drug reactions or allergies was reported. On 19-SEP-2015, the patient was vaccinated with an improperly stored dose of ROTATEQ orally, lot # K010221, expiration date 12-MAY-2016 (strength and dose were not provided). No adverse symptoms were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Initial information has been received from a physician concerning a 14 year old female patient who received the second dose of GARDASIL and experienced "swelling and edema of the eye" and saw treatment at ER where she was given BENADRYL. The physician stated that she had the same experience after the first dose. The patient was due for her third dose in about a week and she was planning on receiving it. The swelling resolved after about a week, the patient had recovered. Follow up information has been received from a registered nurse concerning the 15 year old (initial reported as 14 year old) female patient who on 04-SEP-2008 was vaccinated with the first dose of GARDASIL (Lot # 0250X) and concomitantly received the second dose of HAVRIX (Lot # AHAVB264A). On 02-JAN-2009, the patient received the second dose of GARDASIL (lot# 0947X). On 24-Jun-2009, the patient was seen by the physician with complaints of a cough and wheezing. At the time of the physician's visit the patient's father stated that after the patient had received the first dose of GARDASIL, the patient was ill and nauseous and missed 1 week of school. The patient also had swelling and edema of both eyes. After the patient received the second dose of GARDASIL, the patient had swelling and edema of both eyes. The patient went to the Emergency Room and was treated with BENADRYL (route unknown to the reporter). The patient was not admitted to the hospital. The registered nurse stated that the patient was scheduled to receive the third dose of GARDASIL on 29-JUN-2009. The registered nurse requested to speak with a Merck physician prior to administering the third dose of GARDASIL to the patient. Follow up information has been received from a memo indicated that a Merck physician had spoken to the registered nurse. They have decided to not administer the third dose on 29-JUN-2009. Missing 1 week of school was considered to be disabling by the physician. Additional information has been requested.
Severe Migraine that has never gone away, constant pain. Tried all different medications including headache meds, heart/blood pressure meds, pain meds, other kinds as well. Now I'm seeing a neurologist but nothing has helped.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 03-JAN-2013, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 22-OCT-2013, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Hair Loss; Backache; Nausea; Fever; Headache; Muscle aches; This spontaneous case was reported by a patient and describes the occurrence of ALOPECIA (Hair Loss), BACK PAIN (Backache), NAUSEA (Nausea), PYREXIA (Fever) and HEADACHE (Headache) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Penicillin allergy and Iodine allergy. Concomitant products included CYANOCOBALAMIN (VIT B12) for Vitamin supplementation.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jan-2021, the patient experienced BACK PAIN (Backache), NAUSEA (Nausea), PYREXIA (Fever), HEADACHE (Headache) and MYALGIA (Muscle aches). On 01-Feb-2021, the patient experienced ALOPECIA (Hair Loss). The patient was treated with BIOTIN (oral) ongoing since an unknown date for Hair loss, at a dose of 500 microgram. On 16-Jan-2021, BACK PAIN (Backache), NAUSEA (Nausea), PYREXIA (Fever), HEADACHE (Headache) and MYALGIA (Muscle aches) had resolved. At the time of the report, ALOPECIA (Hair Loss) had not resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       The patient had never been diagnosed with/ tested positive for COVID-19 Indication for concomitant medication Vit B12 was reported as Energy Recent changes in condition status for Alopecia started on 01-Feb-2021 was reported as hair loss.   This case was linked to MOD-2022-584185, MOD-2022-596478 (Patient Link).
Guillain-Barre Synd w/onset 10 days p/flu vax;
Initially complained to supervisor of severe headache, Supervisor to her to go ho home. On 2/10/17 went to ER for headaches. Then on 2/14/17 taken by ambulance to ER for seizures and released Feb 25. 2017.
Patient reported having an adverse reaction to both her first and second Moderna Covid vaccination.  She stated that she felt a burning sensation inside her body and it was very painful.  She said the pain was particularly bad in her eyes. It started about 2 hours after her first vaccine and lasted for "days" after.  She went to her doctor who instructed her to take benadryl.  The benadryl helped with her symptoms which eventually all resolved.   He advised her to go ahead and get her second vaccine as she was high risk for COVID.  When she received her second vaccine she pre-medicated with Benadryl. She said she had the same reaction with her second vaccine but it was much milder.
diaphoretic; hypotensive; This is a spontaneous report from a contactable consumer (patient's mother).  A 34-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) intramuscular, administered in Arm Left on 02May2021 15:20 (at the age of 34-years-old) (Batch/Lot Number: EW0171; Expiration Date: 31Aug2021) as single dose for covid-19 immunisation.  The patient had not medical history. The patient's concomitant medications were not reported.  12 minutes after receiving the vaccine, the patient became hypotensive and diaphoretic for about 1 to 1.5 minutes. He was scheduled for his second dose on 23May2021. The outcome of the events was recovered. The events were assessed as serious, medically significant.   No follow-up attempts are needed. No further information is expected.
Myalgia, Arthralgia, Fever, fatigue Narrative: on Saturday 1/9/21, had fever of 100.3, muscle and joint aches and fatigue; Sunday 1/10/21-milder joint and muscke aches, temperature between 98.6 and 99.6 fluctuating thru the day, Monday 1/11/21- temperature WNL (98.6), still some fatigue- able to work though
Drowsiness; pain at the injection site; skin itching; slight neck pain; lightheaded; felt hot; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ewolso) via an unspecified route of administration in the left arm on 07Apr2021 at 18:45 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. Medical history included contact dermatitis, asthma, skin allergies hypothyroidism, depression, anxiety, year-round allergies and was allergic to gluten and soy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021, the patient experienced drowsiness, pain at the injection site, skin itching, slight neck pain, lightheaded and felt hot. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events drowsiness, pain at the injection site, skin itching, slight neck pain, lightheaded and felt hot was recovering at the time of the report.  No follow-up attempts are needed. No further information is expected.